Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting

Background: Proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduce ischemic events; however, the cost-effectiveness remains uncertain. This study sought to evaluate its economic value in patients with myocardial infarction (MI) from the Chinese healthcare perspective. Methods: A s...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Zhe, Chen, Qi, Wei, Ruiqi, Ma, Chenyao, Zhang, Xuehui, Chen, Xue, Fang, Fang, Zhao, Quanming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080443/
https://www.ncbi.nlm.nih.gov/pubmed/33935749
http://dx.doi.org/10.3389/fphar.2021.648244

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080443/
https://www.ncbi.nlm.nih.gov/pubmed/33935749
http://dx.doi.org/10.3389/fphar.2021.648244

Ejemplares similares